Thanks, lasting Vince. be and to to in developed assembled am Given. joining the fantastic a thanking R&D job like Dr. to Bruce's I have start He by all today. for afternoon, us I'd or everyone did true know execute Bruce innovation you a worked of we instilling confident organization team clear thank contributions will are that a fashion. continue Good developing who culture the to him, Arrowhead and have him, with that us enable right legacy. to and and
page and and next executives prosper seasoned position very during Jim are put this their Arrowhead professionalizing a expanding have Javier, are respective to and Curt who strong functions, in growth.
make intend XXXX Arrowhead gain expand the This options with shareholders to rapidly the catalyst to patients in with provide we year could hope is liver We we RNAi our much lung our provide of the clinical pipeline in then pipeline solid tumors promise value outside new treatment and reality. and hepatocyte-targeted XXXX. the that and XXXX a as for growth. continued did and proof-of-concept
of we expand we're to as also as reach, to While our are risk much of can. looking course squeeze looking we out our business
have on this front. We made good also progress
capitalized. well are we First,
people We've clinical who been XXX our treated by with this human are a XXX all does have the not treated developing across programs. total mind validated candidates. subjects doses of and platform Amgen an that, our And Janssen include in keep with we Second, partner increasingly TRiM. in
programs. well in experts And validated. are medical are view are player sixth, our first gene as addressing validated generally that Third, an the needs. we clinical addressing increasingly RNAi RNAi we is we modality. Fifth, Fourth, targets all unmet of
in call this be of to lens footing, this how our high-level the to my portion through of provide at us a the you which will affected they room outbreak. has of overview and least our use Therefore, This puts near view solid the by programs business risk but is elephant on the COVID-XX. in the midterm. All I may
March, with ARO-AAT in SEQUOIA X-week start alpha-X at liver disease. our open-label medicine against study Let's investigational Phase patient study. for least AROAATXXXX voluntarily a II/III the screening paused new and In period we enrollment the
resuming Any now continue to already are and visits. begin patients follow-up in investigators screening to dosed working We come of enrollment. enrolled in be per to these the with their studies for and continue sites process and protocol
of Importantly, not out been protocol deviations the ordinary. have
Before are enrollment are fall XXXX the pause, collect summer. study, the those still on the at data to in the of biopsies to venue. cohort first we schedule intend we in the already in six-month enrolled appropriate We report fully an so
and We program the believe an this is field. readout the for important
early it pace measuring break and This of While clear will what which doing which we misfolded the give the that and may compare a hepatocytes to to This underlines production the in in in levels assessed polymer. pre- polymerized reported are the field, anywhere. at activity mutation. and for protein, indication liver approaches, date, to as position which alpha-X data down lead but don't in readout is mutant our an amount monomer disease important disease expect interesting its amount is to these the will field. patients the data developing post-treatment us to AAT by changes none other see accumulated might both be are root is of be leaders thought we We There expect substantial be it the can reduce and first tolerability it volunteers. have with view our ZZ and based of believe in normal drug liver hepatocytes. of pharmacologic provide RNAi histological this cause AAT healthy treatment short protein. the demonstrating for Further, is AAT us the do, and to a that treatment, kind the new after homozygous even of progressive This of of designed
be In of serious hopes allowing show approaches to approach by for AAT deficiency it patients protein exported are challenges some that to other clinical of in manifestations hepatocytes. AAT deficiency. addition, treating with more see to correcting benefit from there efficiently We mutant liver AAT the
likely an so to First, the estimated of administer two the grams liver accumulate to is protein liver. some protein of We production, that we AAT portion small produces per day. corrector level it in believe not molecule feasible do think will still enough address
protein goal which for is of mean the would the to corrector correct handle. So still a of large protein, to amount a to XX% is XX% liver very present, the lot would that XX% of is misfolded require XX% still which to
believe nearly that data suppressing years of Our may suggests Z-AAT we the to production that completely treatment ARO-AAT of show and two histology. meaningful take protein, it liver change a liver is mutant in still
a have treat in Z-AAT X is would a corrector gives think serious that setting majority years? leaving large how So we in a you protein that a us the clinical liver, trial position. challenge a strong presents with competitive in and to that long of years, XX We are confidence
two and the about Let's now ARO-ANGX. of talk our cardiometabolic ARO-APOCX candidates, status
high treatment ARO-APOCX history severe developed risk patients and for potential is as with of or being pancreatitis. a hypertriglyceridemia
polygenic such and familial the for single multifactorial high room patients FCS emergency is severe their and this MCM and and of condition visits have Some abdominal pancreatitis, even alone. These with causes syndrome, severe are cost are a both their and cause or disease, MCM, or very life there manifestations. lead can we system. to of chylomicronemia called to both in pain, patients around the This these genetic care with There come the for death. as chylomicronemia, have population patients' recurrent economic but significantly FCS, a believe cost to a similar hypertriglyceridemia. has respect XX,XXX US very health clinical diseases larger with that quality hospitalizations
are MCM working study to potentially focus for a MCM have on a the in We pivotal on plan decided and patients. population
intend to We directly a sufficient discuss a to study. key to design We considerations and data this Phase with a I/II meeting to for to study. registrational the provide III study designed enrolling the enable some year Phase EMA FDA request study
We will relatively continue believe that believe study, the short a could with of to our a XXXX. half study ARO-APOCX our we we first can regulators, is start we speak that know should first market be but be We that more so after pivotal hope in product.
study. a We this intend we later data plan will continue substantial present generate I/II the It present fully to amount we times this and that data to the already that nearly enrolled delay we We that patients. may are various set slight a COVID-XX full the -- experienced prior to to be was accruing hopeful year able have remaining of Phase in data and have we in outbreak year. at a
releases medical is traditional because what outbreak, the take. will unclear to these With form the disruptions the COVID-XX cycle data of it meeting
be are The We alternative to that present ways to have to canceled continue expect finding committed continue. or and trend meetings if we exciting, postponed. early been to data data medical
on last is a thousands, have This patients magnitude a circulating patients hypertriglyceridemic for of truly the after be we we only dose so seen to expect in As patients reduction of These triglycerides would like our XX% reduction call, we this conference reported have approximately triglycerides meaningful ARO-APOCX. of single quite stunning. these. in
mixed being a treatment slightly dyslipidemia. in a are is with as ARO-ANGX, which patients advanced developed with position potential We more for
a Let's talk about that for patient population moment.
treatments risk both that of triglycerides very that million evidence LDL-cholesterol cardiovascular This elevated PCSKX than an elevated not to people have Mixed a is triglycerides higher heightened to atheroslerotic alone. care. prevalence a receptor-mediated in between of standard dyslipidemia with to population non-LDL risk. also disease. ARO-ANGX We There able LDL and potential reduce XX making is disease with both estimated XX reduction inhibitors strong available and at degree patient LDL million and potentially and are the contribute reduce to are potentially current US patients high manner, far see other a alone greater with triglycerides and statins in and addressed than of LDL adequately being
that As approximately with XX% reduction We in we single I patient data at and impressive. after reduction only LDL ARO-APOCX, a of ARO-ANGX. and reported call, believe was in last our conference dose XX% triglycerides saw early
dyslipidemia treatment experts and patients these strongly of reduction show in mixed cardiovascular events were patients patient believe all would is already a and are ANGPTLX and need treated. such reduction also in to quite Importantly, mechanism PCSKX the new study of field most options, we in large LDL-lowering very inhibitors. expect The large. statins on pivotal that believe a drugs, be the as think We we address to is of population
likely for we study year on population, So look we run of this prevalence regulatory indication. that of high IIb are to what like will would instead Because now and development a the path need our determining focus this Phase a directly ARO-APOCX. FDA with the the may study as in and into We of to do we initiate roll hope plan Xb half to in first pivotal XXXX. engaging on Phase able be with
expect The report fully good The year patients X/X in the environment. is study full We we will and data even opportunities real to subsets and delays not making to is we dataset as will a so also enrolled, progress, we follow to share data. believe do ARO-ANGX any continue look throughout generate Phase year. in have the COVID-XX study later for the
will alternative we data, if ARO-APOCX, to postponed. assess like or continue medical be present to ways meetings canceled Just
in carcinoma now to we CTA to our renal IND recently. non-alcohol-related newest would in treat ARO-HIFX alcohol December; an filed for a clear to filed cell development treat filed development for to liver of which cystic like cell a to the we which in ARO-ENaC form CTA and I in ARO-HSD treat clinical December; on move in fibrosis, and disease, candidates: which development for we
X enrolling to ARO-HIFX We begin Phase study shortly. expect the
the and study The and We have centers, one open likely first safety health this for investigators process patients experiencing dosed has quarter. screening COVID-XX. taken academic than the process we will the and anticipate and initiation for and delays this in enrollment due longer we to be is contracting part of to precautions. due Many site may be now at hoped, which are start-up
tight next timing data should for proof-of-concept this until candidate the year. and tumor year, may we for have report too platform pace the We the potentially enrollment. a publicly see as anything to better TRiMTM be to expect targeted this have the idea of but about We
targets concept, with our collaboration proof have additional program about thinking in intend we potentially build of we and already are out the partner. once tumor and the to pipeline on a clinical for own We
biopsies taking So if look current the are success does like from be we X? HifX-alpha the good for will happy Phase what be knockdown, will that we and metastases we right We see track. on
the patients of expectation patients. approximately for be HifX-alpha helpful who target because hippel a von cell First, have validated RCC ARO-HifX an XX% is for these would have with lindau well clear we the could that mutation,
concept just intended types we is tumor HifX-alpha strategy targets. We broad clinical rather a targeting knocking across value suggest tumor are knockdown down hifX-alpha, scalable franchise. proof to new view tumors might different is that solid solid RCC, rapid our our than would have to goal quickly creation work of a strategy. we against into and because Second, Once new achieve expand we that is solid in this
in a dosing X/X in Phase began study March. ARO-HSD
healthy the We higher cohort was paused, New received dose. restrictions expect for are committee shortly volunteers but related the in and escalate to sometime the first second COVID-XX Zealand, we through after we this of patients safety approval enrollment and it previously cohort monitoring Because that. re-open next from of to to
is a to enrollment site have or lasting any our delay on the effects minor and on will this only general think don't believe with are the We plans timelines. program working we that restart
filed For in any we begin largely in Fibrosis. couple too CTA to on months a related study and program. beyond. delays a early COVID-XX this there volunteers Phase depends month It's with in if of patients happens healthy what next ARO-ENaC, the in Cystic last will be That to X/X say and
generate that we and abstract we by by data enough the will belief present proxy pulmonary but Our to data scientific will don't have year. if of at to is platform, know we the and this able be conferences deadlines compound, on data the activity key safety
been help. those no an benefit who genetic b of even several who indication amount channel of There ARO-ENaC ENaC. to opportunities We the form an of But several respond I that CF validation decades as CF-related complication a patients options. mucociliary improve care; patients want even years helps good to is in and CF in a essentially clearance. regardless over standard better. gene mild help of target may we is life. help has don't heterozygous expression to reduction enormous Clearly to CF to there of therapeutic ENaC with into the that or the dehydrated the there do respond epithelial and of those about this ENaC all The also are knockouts have lung discernible mucus that lung CF inhibition may idea last make genotype. ENaC The or see rehydrate is talk that progress sodium CF treatment the are patients hope still briefly
as us expand supportive this study a the pipeline and important we a population. for readout further efficacy to launch candidates study and potentially is both first both Importantly, target to in broadly. for on underserved in move tolerability hope inflection product diseases, pulmonary give other to that and data the address are Phase pulmonary and designed a XXXX patient the be ARO-ENaC development This platform, pulmonary rapidly If point could asthma, the of such COPD, X with fibrosis. value
on and have our ARO-LungX and next our that work candidate. optimization as Toward have I'm lung-targeted to second nominated that we pleased discovery announce completed goal, program
the point, at we but address it to this disclosing that is can not COPD target say designed patients. are We
been data in and are We ARO-ENaC encouraged expansion eager our the to pulmonary and program very franchise. by begin have this the of for
happen has are by manufacturing filing CTA and of toxicology hoped the first-in-human slowed of had but begin down the previously will We two of by first studies. plan this the quarters. or on human one now a studies in bit ARO-LungX studies to working first year, probably XXXX IND-enabling could in We on half and delay and end COVID a development
and past, the play rapidly-expanding in that establishing start you we seeing now. to have excitement franchise are our a out In discussed pulmonary
a tolerated years, delivery be we that have inhaled and Given primate our will in confidence humans. sheep in degree active of our well models and spanning studies high several rodents,
Further, address the lung number that represents a to a of target-rich indications ways. environment us enables innovative in
a as a and this driver see our for we opportunity for shareholders. significant patients So big value
to to addition have people coronavirus. In asked asthma COPD, inhaled CF, TRiM applying about and us IPF
work that possible any happy have the program novel an active have report coronavirus previously causes We to pulmonary-borne that other disclosed current COVID-XX pathogens. address but not future to are and we today
we or about details strategy more this program disclosing the to not are provide the We update. but wanted
the are we that looking to to thinking ingenuity Hepatitis innovative approach this revolutionizing to the We and bring same in B. issue did
All we Arrowhead in a global and of play development say in drug fight. role have improving joined us work that is to and health biopharma proud the
pulmonary-borne A us an number give coronavirus packages. the play important future current of factors confidence and we that other role could coronaviruses in novel in
leading a RNAi First the arguably and any faster than third you RNAi leaders. inhaling look HBV we lung program. and and addressing have program; are are history biotech clinic; going clear second forward in in known and this are any we RNAi suggests leaders We to we with company company up-to-date as company keeping the progress thought other that concept to from antivirals clinic-ready on are
like I'd muscle-targeted to our mention program is final The program.
the need, consistent our company of We indication first candidates. target to target have validated not the disclosed there. the view initial gene medical RNAi a unmet the gene having with as substantial programs expect other yet our well is we indication we first or clinical be and But
the solid as clinical and CTA of very address proof-of-concept end XXXX. We with muscle and into our new franchises we we track indications pipeline a by to remain our muscle to a delivery. spear. the As end expect skeletal tumor ability pulmonary addressable achieve expand gene rapidly view to the targets sharp of Once we on via file
company depth unmatched pipeline the have unmatched diverse of for believe we clinic to I indications, a size. of speed unmatched reach and into our
chronic in working two the against together Phase conduct well. recent year. good study to and on its continues begin Phase second with stated studies HBV call targets. three Janssen first JNJ-XXXX are actively its a this on additional to we IIb expects half it with of XXX to continue as programs Amgen partner quarterly that conference undisclosed Our II the AMG look
COVID-XX that countless important potentially adapting. has medicines Arrowhead help challenges believe new have a introduced can but We patients. we set is of new that
feel only programs we environment caused that well So the very current resourced. our are we has fortunate development and minor delays that to
as to Our employees continue these innovative inspiration focus, to during waned me their difficult times. never ethic be great a work have and spirit
overview, to turn San call Javier? like Dr. the Javier I'd that over now With Martin. to
